[1]
|
Modiano, D., Luoni, G., Sirima, B.S., Lanfrancotti, A., Petrarca, V., Cruciani, F., Simporé, J., Ciminelli, B.M., Foglietta, E., Grisanti, P., Bianco, I., Modiano, G. and Coluzzi, M. (2001) The Lower Susceptibility to Plasmodium falciparum Malaria of Fulani of Burkina Faso (West Africa) Is Associated with Low Frequencies of Classic Malaria-Resistance Genes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 149-152. https://doi.org/10.1016/S0035-9203(01)90141-5
|
[2]
|
Ouattara, A.K., Bisseye, C., Bazie, B.V., Diarra, B., Compaore, T.R., Djigma, F., Pietra, V., Moret, R. and Simpore, J. (2014) Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Is Associated with Asymptomatic Malaria in a Rural Community in Burkina Faso. Asian Pacific Journal of Tropical Biomedicine, 4, 655-658. https://doi.org/10.12980/APJTB.4.2014APJTB-2014-0100
|
[3]
|
Ouattara, A.K., Yameogo, P., Diarra, B., Obiri-Yeboah, D., Yonli, A., Compaore, T.R., Soubeiga, S.T., Djigma, F.W. and Simpore, J. (2016) Molecular Heterogeneity of Glucose-6-Phosphate Dehydrogenase Deficiency in Burkina Faso: G-6-PD Betica Selma and Santamaria in People with Symptomatic Malaria in Ouagadougou. Mediterranean Journal of Hematology and Infectious Diseases, 8, e2016029. https://doi.org/10.4084/mjhid.2016.029
|
[4]
|
Ouattara, A.K., Yameogo, P., Traore, L., Diarra, B., Assih, M., Compaore, T.R., Obiri-Yeboah, D., Soubeiga, S.T., Djigma, F.W. and Simpore, J. (2017) Prevalence, Genetic Variants and Clinical Implications of G-6-PD Deficiency in Burkina Faso: A Systematic Review. BMC Medical Genetics, 18, Article No. 139. https://doi.org/10.1186/s12881-017-0496-2
|
[5]
|
Simpore, J., Ilboudo, D., Damintoti, K., Sawadogo, L., Maria, E., Binet, S., Nitiema, H., Ouedraogo, P., Pignatelli, S. and Nikiema, J.B. (2007) Glucose-6-Phosphate Dehydrogenase Deficiency and Sickle Cell Disease in Burkina Faso. Pakistan Journal of Biological Sciences, 10, 409-414. https://doi.org/10.3923/pjbs.2007.409.414
|
[6]
|
Luzzatto, L., Ally, M. and Notaro, R. (2020) Glucose-6-Phosphate Dehydrogenase Deficiency. Blood, 136, 1225-1240. https://doi.org/10.1182/blood.2019000944
|
[7]
|
Uyoga, S., Ndila, C.M., Macharia, A.W., Nyutu, G., Shah, S., Peshu, N., Clarke, G.M., Kwiatkowski, D.P., Rockett, K.A. and Williams, T.N. (2015) Glucose-6-Phosphate Dehydrogenase Deficiency and the Risk of Malaria and Other Diseases in Children in Kenya: A Case-Control and a Cohort Study. The Lancet Haematology, 2, E437-E444. https://doi.org/10.1016/S2352-3026(15)00152-0
|
[8]
|
Ndila, C.M., Uyoga, S., Macharia, A.W., Nyutu, G., Peshu, N., Ojal, J., Shebe, M., Awuondo, K.O., Mturi, N., Tsofa, B., Sepúlveda, N., Clark, T.G., Band, G., Clarke, G., Rowlands, K., et al. (2018) Human Candidate Gene Polymorphisms and Risk of Severe Malaria in Children in Kilifi, Kenya: A Case-Control Association Study. The Lancet Haematology, 5, E333-E345. https://doi.org/10.1016/S2352-3026(18)30107-8
|
[9]
|
Clarke, G.M., Rockett, K., Kivinen, K., Hubbart, C., Jeffreys, A.E., Rowlands, K., Jallow, M., Conway, D.J., Bojang, K.A., Pinder, M., Usen, S., Sisay-Joof, F., Sirugo, G., Toure, O., Thera, M.A., et al. (2017) Characterisation of the Opposing Effects of G6PD Deficiency on Cerebral Malaria and Severe Malarial Anaemia. eLife, 6, e15085.
|
[10]
|
INSD (2022) Burkina Faso—COVID 19 Rapport de Situation. Burkina Faso Open Data. https://burkinafaso.opendataforafrica.org//jovpdge/burkina-faso-covid-19-rapport-de-situation
|
[11]
|
WHO (2022) Burkina Faso: WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data. https://covid19.who.int/region/afro/country/bf
|
[12]
|
Tegally, H., San, J.E., Cotten, M., Moir, M., Tegomoh, B., Mboowa, G., Martin, D.P., Baxter, C., Lambisia, A.W., Diallo, A., Amoako, D.G., Diagne, M.M., Sisay, A., Zekri, A.-R.N., Gueye, A.S., et al. (2022) The Evolving SARS-CoV-2 Epidemic in Africa: Insights from Rapidly Expanding Genomic Surveillance. Science, 378, eabq5358. https://doi.org/10.1126/science.abq5358
|
[13]
|
Sagna, T., Ouedraogo, P., Traore, L., Obiri-Yeboah, D., Yonli, A., Tapsoba, A., Tovo, F., Sorgho, A., Zongo, L., Nikiema, O., Ilboudo, D., Belemgnegre, M., Nadembega, C.W., Ouermi, D., Djigma, F.W., et al. (2022) Enigma of the High Prevalence of Anti-SARS-CoV-2 Antibodies in HIV-Positive People with No Symptoms of COVID-19 in Burkina Faso. Journal of Public Health in Africa, 13, Article No. 1778. https://doi.org/10.4081/jphia.2022.1778
|
[14]
|
Sagna, T., Ouedraogo, H., Zouré, A., Zida, S., Compaore, R., Kambire, D., Soubeiga, S., Ouedraogo, O., Djigma, F., Zongo, D., Tarnagda, G., Valea, D., Dabiré, C., Nikiema, A., Camara, M., et al. (2021) Le Laboratoire à l’épreuve de la pandémie de la COVID-19 au Burkina Faso: Quels défis pour la régularité de l’offre de diagnostic. Revue Malienne d’Infectiologie et de Microbiologie, 16, 32-37. https://doi.org/10.53597/remim.v16i1.1758
|
[15]
|
Zoure, A.A., Ouedraogo, H.G., Sagna, T., Compaore, T.R., Soubeiga, S.T., Cisse, K., Kambire, D., Ouedraogo, O., Zida, S. and Dabire, C. (2022) Molecular Diagnosis of COVID-19 in Burkina Faso: Successful Challenge. International Journal of Biological and Chemical Sciences, 16, 440-463. https://doi.org/10.4314/ijbcs.v16i1.37
|
[16]
|
Jamerson, B.D., Haryadi, T.H. and Bohannon, A. (2020) Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19? Archives of Medical Research, 51, 743-744. https://doi.org/10.1016/j.arcmed.2020.06.006
|
[17]
|
Jain, S.K., Parsanathan, R., Levine, S.N., Bocchini, J.A., Holick, M.F. and Vanchiere, J.A. (2020) The Potential Link between Inherited G6PD Deficiency, Oxidative Stress, and Vitamin D Deficiency and the Racial Inequities in Mortality Associated with COVID-19. Free Radical Biology and Medicine, 161, 84-91. https://doi.org/10.1016/j.freeradbiomed.2020.10.002
|
[18]
|
MESRSI (2020) Les données préliminaires de l’étude CHLORAZ indiquent un bénéfice du traitement avec la combinaison Hydroxychloroquine + Azythromicine chez les patients de la Covid-19 au Burkina Faso. https://www.mesrsi.gov.bf/fileadmin/user_upload/storage/COMMUNIQUE_DE_PRESS_RESULTATS_PRELIMINAIRES_DE_L_ETUDE_CHLORAZ.pdf
|
[19]
|
De Franceschi, L., Costa, E., Dima, F., Morandi, M. and Olivieri, O. (2020) Glucose-6-Phosphate Dehydrogenase Deficiency Associated Hemolysis in COVID-19 Patients Treated with Hydroxychloroquine/Chloroquine: New Case Reports Coming Out. European Journal of Internal Medicine, 80, 103. https://doi.org/10.1016/j.ejim.2020.08.015
|
[20]
|
Rouamba, T., Barry, H., Ouédraogo, E., Tahita, M.C., Yaméogo, N.V., Poda, A., Diendéré, A.E., Ouedraogo, A.S., Valea, I., Koné, A.M., Thiombiano, C., Traoré, I., Tarnagda, Z., Sawadogo, S.A., Gansané, Z., et al. (2021) Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. Therapeutics and Clinical Risk Management, 17, 1187-1198. https://doi.org/10.2147/TCRM.S330813
|
[21]
|
Rouamba, T., Ouédraogo, E., Barry, H., Yaméogo, N.V., Sondo, A., Boly, R., Zoungrana, J., Ouédraogo, A.R., Tahita, M.C., Poda, A., Diendéré, A.E., Ouedraogo, A.S., Valea, I., Traoré, I., Tarnagda, Z., et al. (2022) Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso. International Journal of Infectious Diseases, 118, 224-229. https://doi.org/10.1016/j.ijid.2022.02.034
|
[22]
|
Stawicki, S.P., Jeanmonod, R., Miller, A.C., Paladino, L., Gaieski, D.F., Yaffee, A.Q., De Wulf, A., Grover, J., Papadimos, T.J., Bloem, C., Galwankar, S.C., Chauhan, V., Firstenberg, M.S., Di Somma, S., Jeanmonod, D., et al. (2020) The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. Journal of Global Infectious Diseases, 12, 47-93. https://doi.org/10.4103/jgid.jgid_86_20
|
[23]
|
Worldometer (2022) COVID Live—Coronavirus Statistics. Worldometer.
|
[24]
|
Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., Seng, P., Hocquart, M., Eldin, C., Finance, J., Vieira, V.E., et al. (2020) Clinical and Microbiological Effect of a Combination of Hydroxychloroquine and Azithromycin in 80 COVID-19 Patients with at Least a Six-Day Follow up: A Pilot Observational Study. Travel Medicine and Infectious Disease, 34, Article ID: 101663. https://doi.org/10.1016/j.tmaid.2020.101663
|
[25]
|
Hache, G., Rolain, J.M., Gautret, P., Deharo, J.C., Brouqui, P., Raoult, D. and Honoré, S. (2021) Combination of Hydroxychloroquine Plus Azithromycin as Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Microbial Drug Resistance, 27, 281-290. https://doi.org/10.1089/mdr.2020.0232
|
[26]
|
Baguiya, A., Poda, A., Cissé, K., Sondo, A., Ouedraogo, B. and Ouedraogo, A. (2021) Effect of Hydroxychloroquine or Chloroquine and Azithromycin on COVID-19 Patients’ Recovery and Mortality: Evidence from a Hospital Based Retrospective Cohort Study Conducted in Burkina Faso. Journal of Infectious Diseases and Epidemiology, 7, Article No. 192. https://doi.org/10.23937/2474-3658/1510192
|
[27]
|
Cappellini, M.D. and Fiorelli, G. (2008) Glucose-6-Phosphate Dehydrogenase Deficiency. Lancet, 371, 64-74. https://doi.org/10.1016/S0140-6736(08)60073-2
|
[28]
|
Howes, R.E., Dewi, M., Piel, F.B., Monteiro, W.M., Battle, K.E., Messina, J.P., Sakuntabhai, A., Satyagraha, A.W., Williams, T.N., Baird, J.K. and Hay, S.I. (2013) Spatial Distribution of G6PD Deficiency Variants across Malaria-Endemic Regions. Malaria Journal, 12, Article No. 418. https://doi.org/10.1186/1475-2875-12-418
|
[29]
|
Luzzatto, L. and Seneca, E. (2014) G6PD Deficiency: A Classic Example of Pharmacogenetics with On-Going Clinical Implications. British Journal of Haematology, 164, 469-480. https://doi.org/10.1111/bjh.12665
|
[30]
|
Ho, L. and John, R.M. (2015) Understanding and Managing Glucose-6-Phosphate Dehydrogenase Deficiency. The Journal for Nurse Practitioners, 11, 443-450. https://doi.org/10.1016/j.nurpra.2015.01.007
|
[31]
|
Luzzatto, L., Nannelli, C. and Notaro, R. (2016) Glucose-6-Phosphate Dehydrogenase Deficiency. Hematology/Oncology Clinics of North America, 30, 373-393. https://doi.org/10.1016/j.hoc.2015.11.006
|
[32]
|
Yang, H.C., Ma, T.H., Tjong, W.Y., Stern, A. and Chiu, D.T. (2021) G6PD Deficiency, Redox Homeostasis, and Viral Infections: Implications for SARS-CoV-2 (COVID-19). Free Radical Research, 55, 364-374. https://doi.org/10.1080/10715762.2020.1866757
|
[33]
|
Da Rocha, J.E.B., Othman, H., Tiemessen, C.T., Botha, G., Ramsay, M., Masimirembwa, C., Adebamowo, C., Choudhury, A., Brandenburg, J.T., Matshaba, M., Simo, G., Gamo, F.J. and Hazelhurst, S. (2021) G6PD Distribution in Sub-Saharan Africa and Potential Risks of Using Chloroquine/Hydroxychloroquine Based Treatments for COVID-19. The Pharmacogenomics Journal, 21, 649-656. https://doi.org/10.1038/s41397-021-00242-8
|
[34]
|
Pérez-Torres, I., Soto, M.E., Guarner-Lans, V., Manzano-Pech, L. and Soria-Castro, E. (2022) The Possible Role of Glucose-6-Phosphate Dehydrogenase in the SARS-CoV-2 Infection. Cells, 11, Article No. 1982. https://doi.org/10.3390/cells11131982
|
[35]
|
Aydemir, D. and Ulusu, N.N. (2020) Is Glucose-6-Phosphate Dehydrogenase Enzyme Deficiency a Factor in Coronavirus-19 (COVID-19) Infections and Deaths? Pathogens and Global Health, 114, 109-110. https://doi.org/10.1080/20477724.2020.1751388
|
[36]
|
Youssef, J.G., Zahiruddin, F., Youssef, G., Padmanabhan, S., Ensor, J., Pingali, S.R., Zu, Y., Sahay, S. and Iyer, S.P. (2021) G6PD Deficiency and Severity of COVID19 Pneumonia and Acute Respiratory Distress Syndrome: Tip of the Iceberg? Annals of Hematology, 100, 667-673. https://doi.org/10.1007/s00277-021-04395-1
|
[37]
|
Wu, Y.-H., Tseng, C.-P., Cheng, M.-L., Ho, H.-Y., Shih, S.-R. and Chiu, D.T.-Y. (2008) Glucose-6-Phosphate Dehydrogenase Deficiency Enhances Human Coronavirus 229E Infection. The Journal of Infectious Diseases, 197, 812-816. https://doi.org/10.1086/528377
|
[38]
|
Littera, R., Campagna, M., Deidda, S., Angioni, G., Cipri, S., Melis, M., Firinu, D., Santus, S., Lai, A., Porcella, R., Lai, S., Rassu, S., Scioscia, R., Meloni, F., Schirru, D., et al. (2020) Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Frontiers in Immunology, 11, Article 605688. https://doi.org/10.3389/fimmu.2020.605688
|
[39]
|
Beauverd, Y., Adam, Y., Assouline, B. and Samii, K. (2020) COVID-19 Infection and Treatment with Hydroxychloroquine Cause Severe Haemolysis Crisis in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency. European Journal of Haematology, 105, 357-359. https://doi.org/10.1111/ejh.13432
|
[40]
|
Palmer, K., Dick, J., French, W., Floro, L. and Ford, M. (2020) Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection. Emerging Infectious Diseases, 26, 2279-2281. https://doi.org/10.3201/eid2609.202353
|
[41]
|
Maillart, E., Leemans, S., Van Noten, H., Vandergraesen, T., Mahadeb, B., Salaouatchi, M.T., De Bels, D. and Clevenbergh, P. (2020) A Case Report of Serious Haemolysis in a Glucose-6-Phosphate Dehydrogenase-Deficient COVID-19 Patient Receiving Hydroxychloroquine. Infectious Diseases, 52, 659-661. https://doi.org/10.1080/23744235.2020.1774644
|
[42]
|
Yu, R., Chen, C.R., Evans, D., Qing, X., Gotesman, M., Chandramohan, G., Kallay, T., Lin, H.J. and Pedigo, T.P. (2022) Glucose-6-Phosphate Dehydrogenase Deficiency Presenting with Rhabdomyolysis in a Patient with Coronavirus Disease 2019 Pneumonia: A Case Report. Journal of Medical Case Reports, 16, Article No. 106. https://doi.org/10.1186/s13256-022-03322-w
|
[43]
|
Kumar, N., AbdulRahman, A., AlAwadhi, A.I. and AlQahtani, M. (2021) Is Glucose-6-Phosphatase Dehydrogenase Deficiency Associated with Severe Outcomes in Hospitalized COVID-19 Patients? Scientific Reports, 11, Article No. 19213. https://doi.org/10.1038/s41598-021-98712-3
|
[44]
|
Lupescu, A., Bissinger, R., Goebel, T., Salker, M.S., Alzoubi, K., Liu, G., Chirigiu, L., Mack, A.F., Qadri, S.M. and Lang, F. (2015) Enhanced Suicidal Erythrocyte Death Contributing to Anemia in the Elderly. Cellular Physiology and Biochemistry, 36, 773-783. https://doi.org/10.1159/000430137
|
[45]
|
Sasi, S., Yassin, M.A., Nair, A.P. and Al Maslamani, M.S. (2020) A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency. American Journal of Case Reports, 21, e925788. https://doi.org/10.12659/AJCR.925788
|
[46]
|
Klouda, C.B. and Stone, W.L. (2020) Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. Antioxidants, 9, Article No. 894. https://doi.org/10.3390/antiox9090894
|
[47]
|
Chaney, S., Basirat, A., McDermott, R., Keenan, N. and Moloney, E. (2020) COVID-19 and Hydroxychloroquine Side-Effects: Glucose 6-Phosphate Dehydrogenase Deficiency (G6PD) and Acute Haemolytic Anaemia. QJM: An International Journal of Medicine, 113, 890-891. https://doi.org/10.1093/qjmed/hcaa267
|
[48]
|
Zhang, P., Gao, X., Ishida, H., Amnuaysirikul, J., Weina, P.J., Grogl, M., O’Neil, M.T., Li, Q., Caridha, D., Ohrt, C., Hickman, M., Magill, A.J. and Ray, P. (2013) An In vivo Drug Screening Model Using Glucose-6-Phosphate Dehydrogenase Deficient Mice to Predict the Hemolytic Toxicity of 8-Aminoquinolines. The American Journal of Tropical Medicine and Hygiene, 88, 1138-1145. https://doi.org/10.4269/ajtmh.12-0682
|
[49]
|
Mohammad, S., Clowse, M.E.B., Eudy, A.M. and Criscione-Schreiber, L.G. (2018) Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients. Arthritis Care & Research, 70, 481-485. https://doi.org/10.1002/acr.23296
|
[50]
|
Ramirez de Oleo, I.E., Mejia Saldarriaga, M. and Johnson, B.K. (2022) Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase. Journal of Clinical Rheumatology, 28, e23-e25. https://doi.org/10.1097/RHU.0000000000001571
|
[51]
|
Schilling, W.H.K., Bancone, G. and White, N.J. (2020) No Evidence That Chloroquine or Hydroxychloroquine Induce Hemolysis in G6PD Deficiency. Blood Cells, Molecules, and Diseases, 85, Article ID: 102484. https://doi.org/10.1016/j.bcmd.2020.102484
|
[52]
|
Zuchelkowski, B.E., Wang, L., Gingras, S., Xu, Q., Yang, M., Triulzi, D., Page, G.P., Gordeuk, V.R., Kim-Shapiro, D.B., Lee, J.S. and Gladwin, M.T. (2020) Brief Report: Hydroxychloroquine Does Not Induce Hemolytic Anemia or Organ Damage in a “Humanized” G6PD A-Mouse Model. PLOS ONE, 15, e0240266. https://doi.org/10.1371/journal.pone.0240266
|
[53]
|
Kongkiatkamon, S. (2022) Acute Haemolysis Following COVID-19 Vaccination in a Thalassaemic Patient with G6PD Deficiency. British Journal of Haematology, 198, 221. https://doi.org/10.1111/bjh.18204
|